Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ines Perez-Roman"'
Autor:
Ines Perez-Roman, Filip Kiekens, Damian Cordoba-Diaz, Juan Jose Garcia-Rodriguez, Manuel Cordoba-Diaz
Publikováno v:
Pharmaceutics, Vol 12, Iss 9, p 873 (2020)
Background: Intestinal nematode infections are usually treated with benzimidazole drugs, but the emergence of resistance to these drugs has led to an increasing demand of new anthelmintic strategies. A new microemulsion formulation (ME) consisting of
Externí odkaz:
https://doaj.org/article/24ed1fa821c645b5b07315804ce2083b
Autor:
Filip Kiekens, Damián Cordoba-Diaz, Juan José García-Rodríguez, Ines Perez-Roman, Manuel Cordoba-Diaz
Publikováno v:
Pharmaceutics, Vol 12, Iss 873, p 873 (2020)
Pharmaceutics
Volume 12
Issue 9
Pharmaceutics
Volume 12
Issue 9
Background: Intestinal nematode infections are usually treated with benzimidazole drugs, but the emergence of resistance to these drugs has led to an increasing demand of new anthelmintic strategies. A new microemulsion formulation (ME) consisting of
Autor:
Damián Cordoba-Diaz, Juan José García-Rodríguez, Manuel Cordoba-Diaz, Ines Perez-Roman, Filip Kiekens
Publikováno v:
NATURAL PRODUCT COMMUNICATIONS
Some species of Artemisia have traditionally been used as anthelmintics. The presence of toxic components in the extracts of these plants, such as alpha- and beta-thujones, and their poor aqueous solubility constitutes important limitations for their
Autor:
Jaime Rodríguez Quintosa, Cintia Cristina Ago, Antoni Sicras Mainar, Renata Villoro, Inés Pérez-Román
Publikováno v:
Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)
Background: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ). Aim: This study assesses the clinical and econo
Externí odkaz:
https://doaj.org/article/95958a75673c488f94ae2a01b65864c7
Autor:
Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román, Almudena González-Domínguez
Publikováno v:
Global & Regional Health Technology Assessment, Vol 8 (2021)
Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in a
Externí odkaz:
https://doaj.org/article/4175ad5d84ca44c7858d1b089c0f955b